ABL1 and Parkinson disease: Genetic depletion of c-Abl protects against loss of dopaminergic neurons in the MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) model of PD (12) and reduces α-synuclein aggregation, neuropathology, and neurobehavioral deficits in the A53T α-synuclein transgenic model of α-synucleinopathy (13).